AZD 4117
Alternative Names: AZD-4117Latest Information Update: 15 Oct 2025
At a glance
- Originator AstraZeneca
- Class Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
Most Recent Events
- 04 Sep 2025 Phase-I/II clinical trials in Influenza A virus H5N1 subtype (Prevention, Combination therapy) in USA (IM) (NCT07128615)
- 04 Sep 2025 Phase-I/II clinical trials in Influenza A virus H7N9 subtype (Prevention, Combination therapy) in USA (IM) (NCT07128615)
- 19 Aug 2025 Preclinical trials in Influenza A virus H5N1 subtype (Prevention) in United Kingdom (IM)